Silencing of <i><scp>DLEU</scp>2</i> suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA‐455

Xu, Bo; Gong, Xufei; Li, Zi; Li, Guang; Dong, Shuxiao; Chen, Xinrui; Li, Yutao

doi:10.1111/cas.13987

Cited by 46 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncR-NAs have emerged as novel potential therapeutic target tools, and studies have demonstrated that lncRNAs are significantly associated with the progression of PC [47]. For example, high DLEU2 levels indicate a poor prognosis for PC patients [12]. SNHG1 inhibits PC cell proliferation, invasion and metastasis by inhibiting the Notch-1 signaling pathway [48].…”

Section: Lncrnas Related To Pcmentioning

confidence: 99%

“…However, DLEU2 is not an independent biomarker for PC prognosis. Thus, the regulation of DLEU2/miR-455/ SMAD2 can be considered a PC therapeutic axis [12].…”

Section: Dleu2mentioning

confidence: 99%

“…LncRNA DLEU2 Up Cell proliferation and invasion [12] HULC LncRNA HULC Up Cell proliferation, migration and invasion [68] PCTST LncRNA PCTST Down Inhibits cell proliferation, invasion, tumorigenesis and EMT [73] lncRNAs can be found in exosomes from tumors, providing a very promising research direction for the diagnosis and treatment of PC. Moreover, some lncRNAs increase the growth of intestinal epithelial cells and organoids in mice [89].…”

Section: Dleu2mentioning

confidence: 99%

“…Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs of more than 200 nt in length and were originally discovered through the large-scale sequencing of mouse cDNA libraries [9][10][11]. They have attracted intense attention in recent years, as evidence shows that lncRNAs are involved in multiple cancer biology hallmarks [12]. In addition, lncRNAs have been widely reported to participate in the transcriptional, posttranscriptional and epigenetic gene regulation of tumor carcinogenesis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know

Zhou

Chen

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the leading causes of cancer-related deaths worldwide. Due to the shortage of effective biomarkers for predicting survival and diagnosing PC, the underlying mechanism is still intensively investigated but poorly understood. Long noncoding RNAs (lncRNAs) provide biological functional diversity and complexity in protein regulatory networks. Scientific studies have revealed the emerging functions and regulatory roles of lncRNAs in PC behaviors. It is worth noting that some in-depth studies have revealed that lncRNAs are significantly associated with the initiation and progression of PC. As lncRNAs have good properties for both diagnostic and prognostic prediction due to their translation potential, we herein address the current understanding of the multifaceted roles of lncRNAs as regulators in the molecular mechanism of PC. We also discuss the possibility of using lncRNAs as survival biomarkers and their contributions to the development of targeted therapies based on the literature. The present review, based on what we know about current research findings, may help us better understand the roles of lncRNAs in PC.

show abstract

Section: Lncrnas Related To Pcmentioning

confidence: 99%

“…However, DLEU2 is not an independent biomarker for PC prognosis. Thus, the regulation of DLEU2/miR-455/ SMAD2 can be considered a PC therapeutic axis [12].…”

Section: Dleu2mentioning

confidence: 99%

Section: Dleu2mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know

Zhou

Chen

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…, acute myeloid leukemia(31), glioma(36), hepatocellular carcinoma(37,38), esophageal cancer(39,40), osteosarcoma(41), and pancreatic cancer(42) tissues and cell lines, and its expression level is related to the patient's prognosis and overall survival closely related. Furthermore, knockdown of lncRNA DLEU2 inhibited the proliferation of AGS and MKN-45 cells, and induced cell apoptosis.…”

mentioning

confidence: 99%

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

Han

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background Gastric cancer (GC) is the fourth common and the second lethal malignancy. Further understanding of the molecular mechanisms of underlying gastric carcinogenesis will enhance the diagnosis and treatment of GC. Methods The expression of lncRNA DLEU2 and ETS2 was analysed using GEPIA online analyze, qRT-PCR and immunohistochemistry. siRNAs targeting to lncRNA DLEU2 were designed to reduce the expression of lncRNA DLEU2. miR-30a-5p mimics were purchased to up-regulate the level of miR-30a-5p. The pcDNA3.1-ETS2 vector was synthesized to up-regulate the expression of ETS2. The biological function of GC cells was detected by CCK8, clone formation, transwell, wound healing, western blot, and flow cytometry assay. More in-depth mechanisms were studied. Results LncRNA DLEU2 was significantly up-regulated in GC tissues. The expression of lncRNA DLEU2 was significantly associated with pathological grading and TNM stage of GC patients. Furthermore, knockdown of lncRNA DLEU2 inhibited the proliferation, migration and invasion of AGS and MKN-45 cells, and induced cell apoptosis. We also found that miR-30a-5p could directly bind to the 3’ UTR region of ETS2. Moreover, lncRNA DLEU2 bound to miR-30a-5p through the same binding site, which facilitated the expression of ETS2. Knockdown of lncRNA DLEU2 reduced the protein level of intracellular ETS2 and inhibited the AKT phosphorylation. ETS2 was highly expressed in GC tissues. The expression of ETS2 was significantly associated with age, pathological grading and TNM stage. ETS2 overexpression promoted cell proliferation and migration of AGS and MKN-45 cells. Furthermore, ETS2 overexpression rescued cell proliferation and migration inhibition induced by lncRNA DLEU2 down-regulation and miR-30a-5p up-regulation in AGS and MKN-45 cells. These results showed that lncRNA DLEU2 may regulate GC cells process through miR-30a-5p/ETS2 axis. In addition, hypoxic microenvironment resulted in the accumulation and nucleation of HIF-1α in gastric cancer cells, and up-regulated the expression of DLEU2. Conclusions LncRNA DLEU2 was a potential molecular target for GC treatment.

show abstract

LncRNA DLEU2 promotes tumour growth by sponging miR‐337‐3p in human osteosarcoma

Liu

et al. 2020

Cell Biochemistry & Function

View full text Add to dashboard Cite

According to statistics, abnormal regulation of lncRNAs pivotally influences multiple malignant tumours. DLEU2, as one of these lncRNAs, is detected to be related to growth and development of tumours. The molecular mechanisms of DLEU2 in osteosarcoma, however, are still unknown. QRT-PCR was adopted to analyse the correlations of clinicopathological features and prognosis of osteosarcoma cases with DLEU2. The influences of DLEU2 on cell migration and viability were evaluated independently by experiments in vitro and in vivo. Bioinformatics analysis, RNA immunoprecipitation (RIP) assay, and dual luciferase reporter gene assay confirmed the specific binding of DLEU2 to miR-337-3p. Moreover, rescue experiments were carried out to further evaluate the regulatory association between miR-337-3p expression and DLEU2. In osteosarcoma tissues and cells, DLEU2 expression level was raised remarkably in comparison with that in para-carcinoma normal tissues, and DLEU2 high expression had associations with poor prognosis, tumour stages, and TS of osteosarcoma cases. Cell migration ability and viability were blocked by DLEU2 knockdown but enhanced by ectopic DLEU2 expression in vitro and in vivo. Additionally, DLEU2 was found to sponge miR-337-3p and trigger the stimulating effect in osteosarcoma cells, which would be suppressed by miR-337-3p mimics. Furthermore, a negative correlation existed between miR-337-3p expression and DLEU2 in osteosarcoma tissues. This study manifests that DLEU2 sponges miR-337-3p to accelerate tumour growth and is confirmed to be a factor for poor prognosis of osteosarcoma cases. Significance of the Study: LncRNA DLEU2 has been reported to be dysregulated in many tumours; however, the functions and underlying mechanism of DLEU2 in osteosarcoma pathogenesis are still unknown. This study is the first to demonstrate the roles of DLEU2 in osteosarcoma and revealed that DLEU2 may serve as a ceRNA to sponge miR-337-3p and then promote the progression of osteosarcoma, providing a potential therapeutic target for osteosarcoma.

show abstract

Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA‐455

Cited by 46 publications

References 30 publications

The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know

The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

LncRNA DLEU2 promotes tumour growth by sponging miR‐337‐3p in human osteosarcoma

Contact Info

Product

Resources

About